23andMe’s fall from fame ends in Regeneron takeover
BBC - 19-May-2025Regeneron buys 23andMe for $256M, pledges to protect user data and boost drug discovery
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, it branched out into the study of both cytokine and tyrosine kinase receptors.
Visit website: https://www.regeneron.com/
Details last updated 05-May-2020
Regeneron buys 23andMe for $256M, pledges to protect user data and boost drug discovery
Regeneron’s DB-OTO offers new hope for genetic hearing loss
Study reveals new insights into obesity, diabetes, and genetic diversity
Corporate shift towards ophthalmology puts senolytics head-to-head against existing treatments
Phase 1 trial reports, single dose of the drug cuts protein levels by 87% in ATTR amyloidosis